Difference between revisions of "Team:Evry/Project/Mait"

 
(16 intermediate revisions by 2 users not shown)
Line 28: Line 28:
 
         <div id="top-menu"></div-->
 
         <div id="top-menu"></div-->
 
         <div class="page-header">
 
         <div class="page-header">
            <h1>RiboVax</h1>
+
<h2>RiboVax, a new vaccinal vector targeting the MAIT Cells</h2>
        </div>
+
<p class="text-justify"> <strong>Mucosal-associated invariant T </strong> (MAIT) cells were first described in 1999 and rapidly became a promisive way to carry out immunotherapy, in particular via recent findings revealing their unique anti-bacterial function. This cells represent the most abundant innate-like T-cell population within human beings, comprising up to ~5% of the total T-cell population. They are characterized by the expression of a semi-invariant <strong>T-cell Receptor</strong>(TCR)(Vα7.2-Jα33/12/20) that recognizes the Major Histocompatibility Complexe (MHC)-like protein 1 (MR1), which presents a bacterial-derived ligand. Furthermore, MAIT cells have been associated with a number of disease settings, including bacterial infections, viral infections, and pro-inflammatory diseases such as multiple sclerosis and psoriasis. Thus, this large T lymphocyte population is likely to have an important role in human health. </p>
<br>
+
 
<h2>A new vaccinal vector targeting the MAIT Cells</h2>
+
<h2>General MAIT cells activation process</h2>
<p> Mucosal-associated invariant T (MAIT) cells were first described by Tilloy et al. In 1999.
+
The interest in this unique subset of innate-like T-cells has increased rapidly over the last 5 years as novel findings have revealed their unique anti-bacterial function. MAIT cells represent the most abundant innate-like T-cell population within human beings, comprising up to ~5% of the total T-cell population. They are characterized by the expression of a semi-invariant TCR (Vα7.2-Jα33/12/20) that recognizes the MHC-like protein 1 (MR1), which presents a bacterial-derived ligand. Furthermore, MAIT cells have been associated with a number of disease settings, including bacterial infections, viral infections, and pro-inflammatory diseases such as multiple sclerosis and psoriasis. Thus, this large T lymphocyte population is likely to have an important role in human health. </p>
+
  
 
<img src="https://static.igem.org/mediawiki/2015/e/ef/Fimmu-05-00450-g001.jpg"  usemap="#imgmap2015916171923" id='image-map-py' width="1024"/>
 
<img src="https://static.igem.org/mediawiki/2015/e/ef/Fimmu-05-00450-g001.jpg"  usemap="#imgmap2015916171923" id='image-map-py' width="1024"/>
  
<map id="imgmap2015916171923" name="imgmap2015916171923"><area shape="circle" alt="" title="" coords="0,0,23" target="" ><area shape="circle" alt="" title="" coords="234,435,24" href="" target="" /><area shape="circle" alt="" title="" coords="348,427,25" href="" target="" /><area shape="circle" alt="" title="" coords="259,351,22" href="" target="" /><area shape="circle" alt="" title="" coords="294,278,24" href="" target="" /><area shape="circle" alt="" title="" coords="596,300,23" href="" target="" /><area shape="circle" alt="" title="" coords="708,194,29" href="" target="" /><area shape="circle" alt="" title="" coords="880,97,27" href="" target="" /><area shape="circle" alt="" title="" coords="784,422,29" href="" target="" /><area shape="circle" alt="" title="" coords="873,526,29" href="" target="" /></map>
+
<p>(1) Internalization of Salmonella by an antigen-presenting cell, either through infection or actively by phagocytosis. (2) Lysis of the bacteria, within endocytic compartments, releases 5-A-RU, which is converted to 5-OE-RU or 5-OP-RU and binds to and stabilizes MR1. (3) The stable MR1 translocates to the cell surface, where it is presented along with other co-stimulatory molecules, e.g., CD80 or CD86. (4) Bacterial components trigger pathogen recognition receptors (PRR), such as TLR8. (5) PRR triggering drives cytokine expression, such as IL-12, and the activation of the inflammosome, resulting in the release of active-IL-18. (6) MAIT cells are activated either by TCR recognition of MR1 in combination with co-stimulatory receptors, e.g., CD28, and/or by cytokines, e.g., IL-12 and IL18. (7) Activated MAIT cells express pro-inflammatory cytokines, e.g., IFNγ, TNFα, and IL-17. (8) These cytokines can directly act anti-bacterially, or recruit and stimulate other immune cells, e.g., neutrophils by IL-17. (9) Activation of MAIT cells upregulates perforin and granzyme B expression. (10) Theoretically, the degranulation of cytotoxic granules into infected cells (target cells), via recognition of MR1, could induce cell death and, thus, the potential clearance of infected cells.</p>
 +
 
 +
<div class="row">
 +
<div class="col-md-4"><img border="0" src="https://static.igem.org/mediawiki/2015/4/4e/Capture_du_2015-09-18_23-37-45.png" alt="" /></div>
 +
<div class="col-md-8">
 +
<p class="text-justify">The <strong>recognition mechanism</strong> of bacterial infections by MAIT cells is based on the bacterial specific riboflavin metabolism (vitamin B2) which is absent in humain beings. This cellular process is dependent of the 5-amino-ribityl-uracil (5-A-RU), an unstable precursor of riboflavin, which attracts the Antigen Presenting Cell (APC) and MAIT cells.</p>
 +
 
 +
<p class="text-justify">The Curie Institute developped an <em>E.Coli</em> strain (Delta RibE BW25113), in which the genomic RibE enzyme has been deleted. This enzyme is involved in the riboflavin biosynthesis, and more precisely in the chemical transformation of the 5-A-RU in RL-6,7-diMe. Thus, these strain accumulates the 5-A-RU, involved in the MAIT cells attraction, and become a promisive vaccinal vector.</p>
 +
 
 +
</p>  
 +
 
 +
<p class="text-justify">Thus the goal is to express in RiboVax some tumoral antigens specific to each patient, in order to bring them to the CMH-I and CMH-II, and carry out an active and personalized immunotherapy. The following picture explains how in details </p>
 +
</div>
 +
 
 +
 
 +
 
 +
 
 +
 
 +
<img src="https://static.igem.org/mediawiki/2015/e/ef/Fimmu-05-00450-g001.jpg" width="1024"/>
 +
 
  
  

Latest revision as of 20:54, 18 September 2015

Scroll to top To top